During the onset of any clinical trial there are many factors and variables to consider. Funding, time restraints, and regulatory agency guidelines are factors that often influence which variables will be studied, leaving other important information out of the study. Preformulation in Solid Dosage Form Development covers every topic of critical importance to the preformulation stages of drug development. Serving as a handbook or stand-alone reference, this text equips those in academia and the pharmaceutical industry with both basic and applied principles for the characterization of drugs, excipients, and products, and deals with the issues relating to predictability, identification, and product development during preformulation stages through Phase I of clinical trials.
With contributions from an international panel of experts in the field, this guide:
- outlines an updated preformulation program for modern drug development issues that includes particle morphology, characterization, thermal analysis, and solubility methods
- contains rational designs for the structure of formulation studies
- covers the importance of preformulation design using artificial neural networks and computational prediction techniques, and examines the concepts of preliminary-preformulation
- discusses the typical drug-excipient interactions that could occur during the course of development and methods of characterization
- includes novel methods to determine the physical and chemical stability of new formulations
- reviews the structure, content, and format of the preformulation report
- examines the significance of drug substance physiochemical properties, in regulatory quality by design
| Prefaces |
|
iii | |
| Contributors |
|
vii | |
|
|
|
|
Introduction and Overview to the Preformulation Development of Solid Dosage Forms |
|
|
1 | (16) |
|
|
|
PART 2: PRELIMINARY PREFORMULATION |
|
|
|
Accelerating the Course of Preliminary Preformulation Through Prediction of Molecular Physical Properties and Integrated Analytical Data Management |
|
|
17 | (24) |
|
|
|
|
|
|
|
Prediction of Crystallographic Characteristics |
|
|
41 | (22) |
|
|
|
Salt Selection for Pharmaceutical Compounds |
|
|
63 | (18) |
|
|
|
|
|
|
|
Intelligent Preformulation Design and Predictions Using Artificial Neural Networks |
|
|
81 | (34) |
|
|
|
PART 3: PROFILING THE DRUG SUBSTANCE |
|
|
|
Developing a Profile of the Active Pharmaceutical Ingredient |
|
|
115 | (30) |
|
|
|
Particle Morphology and Characterization in Preformulation |
|
|
145 | (40) |
|
|
|
Preparation and Identification of Polymorphs and Solvatomorphs |
|
|
185 | (44) |
|
|
|
X-Ray Diffraction Methods for the Characterization of Solid Pharmaceutical Materials |
|
|
229 | (24) |
|
|
|
|
|
Spectroscopic Methods for the Charaeterization of Drug Substances |
|
|
253 | (26) |
|
|
|
Thermal Analysis and Calorimetric Methods for the Characterization of New Crystal Forms |
|
|
279 | (44) |
|
|
|
|
|
Solubility Methods for the Characterization of New Crystal Forms |
|
|
323 | (24) |
|
|
|
PART 4: DEVELOPMENT OF THE IDEAL FORMULATION |
|
|
|
Overview of the Solid Dosage Form Preformulation Program |
|
|
347 | (10) |
|
|
|
Drug-Excipient Interaction Occurrences During Solid Dosage Form Development |
|
|
357 | (80) |
|
|
|
Methodology for the Evaluation of Chemical and Physical Interactions Between Drug Substances and Exeipients |
|
|
437 | (40) |
|
|
|
|
|
477 | (80) |
|
|
|
|
|
PART 5: BEYOND PERFORMULATION |
|
|
|
Strueture. Content, and Format of the Preformulation Report |
|
|
557 | (14) |
|
|
|
Significance of Drug Substance Physicochemical Properties in Regulatory Quality by Design |
|
|
571 | (14) |
|
|
|
|
|
|
| Index |
|
585 | |
MOJI CHRISTIANAH ADEYEYE is currently a Professor of Pharmaceutics and Pharmaceutical Technology, a Fulbright Scholar, and a member of the graduate faculty at the School of Pharmacy, Duquesne University, Pittsburgh, Pennsylvania. She graduated from the University of Nigeria, Nsukka and the University of Georgia, Athens, where she earned her B.S., M.S., and Ph.D. respectively. Her research interests include, preformulation, drug/excipient characterization, delivery systems with a focus on bioavailability and bioequivalence of solid, semi-solid and liquid dosage forms (conventional, modified release). She has worked extensively on nonsteroidal anti-inflammatory drugs, steroids and excipients such as cyclodextrins, microcrystalline cellulose and silicified microcrystalline cellulose. She has published over 40 manuscripts and two patents and given over 100 scientific presentations. She was the past President of the Nigerian American Association of Pharmaceutical Scientists (NAAPS) and former Chair of the AAPS Preformulation Focus Group. She is the Founder and President of a non-profit organizationDrugs for AIDS and HIV Patients (DAHP) whose focus is to care and provide treatment for HIV/AIDS orphans and widows. She is a member of AAPS, APHA, CRS, AACP, AAUP and Christian Connections for International Health.
HARRY G. BRITTAIN is Founder of the Center for Pharmaceutical Physics, Milford, New Jersey. Previously, Dr. Brittain was Vice President for Pharmaceutical Development at Discovery Laboratories, Inc. He also served as Director of Pharmaceutical Development at Ohmeda Inc., and led a variety of groups within the Analytical R&D Department at Bristol-Myers Squibb Co. Dr. Brittain has authored more than 275 research publications and book chapters and has presented numerous invited lectures and short courses in pharmaceutics. He is editor of several books including Physical Characterization of Pharmaceutical Solids, Polymorphism in Pharmaceutical Solids, and Spectroscopy of Pharmaceutical Solids (Taylor & Francis, Inc.). Dr. Brittain is an Associate Editor for the Journal of Pharmaceutical Sciences, and a member of the editorial boards of Pharmaceutical Development and Technology, AAPS PharmSciTech, and Chirality. Dr. Brittain is a Fellow of the American Association of Pharmaceutical Scientists and of the Royal Institute of Chemistry, and a recipient of the AAPS Research Achievement Award in Analysis and Pharmaceutical Quality.
Biežāk uzdotie jautājumi par e-grāmatām